Clinical trial
CPG 7909 in Patients With Cutaneous T-Cell Lymphoma
NCT00043420 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00043420 |
|---|---|
| Title | CPG 7909 in Patients With Cutaneous T-Cell Lymphoma |
| Official title | A Phase I/II Open Label, Multi-Center Study For The Evaluation Of Pf-3512676 (CPG 7909) In Patients With Stage Ib To Iva Cutaneous T-Cell Lymphoma |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, T-Cell, Cutaneous |
| Intervention type | Drug |
| Interventions | PF-3512676 |
| Enrollment | 42 |
| Start date | Jan 1, 2003 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Aug 12, 2002 |
| Last update posted | Feb 12, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: